Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ponsegromab by Pfizer for Cancer Anorexia-Cachexia Syndrome: Likelihood of Approval
Ponsegromab is under clinical development by Pfizer and currently in Phase II for Cancer Anorexia-Cachexia Syndrome. According to GlobalData, Phase...
Ponsegromab by Pfizer for Congestive Heart Failure (Heart Failure): Likelihood of Approval
Ponsegromab is under clinical development by Pfizer and currently in Phase II for Congestive Heart Failure (Heart Failure). According to...
Risk adjusted net present value: What is the current valuation of Pfizer's Ponsegromab?
Ponsegromab is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Cancer Anorexia-Cachexia Syndrome. According to...
Risk adjusted net present value: What is the current valuation of Pfizer's Ponsegromab?
Ponsegromab is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Congestive Heart Failure (Heart Failure)....